Loading company…
Roivant Sciences Ltd. develops late-stage drugs and operates a holding company of biopharmaceutical spinoffs.
Roivant Sciences Ltd. develops late-stage drugs and runs a holding company of spinoffs focused on drug research and development. Founded in 2014 and headquartered in New York, US, the company has over 800 employees and is at the Late stage. Vivek Ramaswamy is the founder and chairman, and Matthew Gline is CEO as of 2021. In October 2021, the company completed a merger with Montes Archimedes Acquisition Corp, a special purpose acquisition company, valued at USD 411 million in cash, and began trading on Nasdaq as ROIV.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in